13.7% growth for Indian pharma recorded 13.7%to $9.43 billion in first three quarters of fiscal 2009-10

The Indian pharmaceutical industry saw turnover grow 13.7% to 434.24 billion rupees ($9.43 billion) for the first nine months of the fiscal 2009-10 year, reveals a monthly report from the market surveillance firm, AIOCD Pharmasofttech AWACS. Revenue for the month of December 2009 was reported at 37.66 billion rupees, up 14.4% on the like, year-earlier period, notes the firm's PharmaTrac, reported by the Indian news service PharmaBiz.

Revenue of the top 10 drugmakers contributed 15.96 billion rupees in the month of December. Cipla remains the leading company with sales of 2.30 billion rupees for the month, up 17.6%, and a total of 23.77 billion rupees for the nine months. Ranbaxy, now majority owned by Japan's Daiichi Sankyo, came second, registering growth of 7.2% to 1.87 billion rupees for the month and 22.1 billion rupees for the three-quarter period, up 7.8%.

GlaxoSmithKline, Piramal Healthcare, Sun Pharmaceuticals, Zydus Cadila, Lupin, Mankind Pharma, Alkem Lab, Aristo Pharma follow Cipla and Ranbaxy in the ranking list.